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SUMMARY
Multiple myeloma is a neoplastic proliferation of 
monoclonal plasma cells. Symptomatic gastrointestinal 
involvement is uncommon. We report the case of a 
45-year-old patient admitted with an anorectal polypoid 
lesion, which progressed to colonic obstruction. 
Investigation revealed a secondary plasmacytoma 
associated with multiple myeloma. We discuss the 
characteristics of this rare entity with poor prognosis, its 
clinical implications and treatment options.
BACKGROUND
Anorectal plasmacytoma is a very rare entity and its 
association with multiple myeloma has never been 
reported to date. We discuss the clinical implica-
tions and the therapeutic options of this condition 
with poor prognosis.
CASE PRESENTATION
A 45-year-old man was admitted to our gastro-
enterology department with a 4-month history of 
diarrhoea, rectal bleeding, tenesmus, abdominal 
pain and weight loss (12% of total body weight). 
His medical history was unremarkable. There 
was neither family history of inflammatory bowel 
disease nor colorectal cancer.
INVESTIGATIONS
Flexible sigmoidoscopy revealed a large polypoid 
lesion that extended from the proximal anal canal 
to the distal rectum, covering about one-third of the 
rectal lumen (figure 1). Proximal colonic mucosa 
was normal. Previous total colonoscopy, performed 
3 months earlier, showed no remarkable patholog-
ical features.
Laboratory evaluation revealed the following: 
haemoglobin 8.7 g/dL, white blood cell count 
6.5×109 cells/L, platelet count 158×109 cells/L, 
urea 47 mg/dL, serum creatinine 2.43 mg/dL, lactate 
dehydrogenase 166 U/L, serum calcium 8.7 mg/dL, 
C reactive protein 14.7 mg/L, serum β2 microglob-
ulin 10.17 mg/L and hypogammaglobulinaemia 
with monoclonal peak (undetectable serum IgM 
and IgA, serum IgG 4.4 g/L). Serum immuno-
fixation revealed monoclonal lambda free light 
chain. A 24-hour urine collection was positive for 
Bence-Jones protein. Bone marrow aspiration and 
biopsy showed 73% of monoclonal plasma cells, 
confirming the diagnosis of lambda light chain 
multiple myeloma.
Histopathological examination of the anorectal 
lesion showed subepithelial plasmacytic cell infil-
tration, and immunohistochemical staining positive 
for CD138 and CD38, and Ki-67 of almost 100%, 
compatible with plasma cell neoplasm (figure 2).
The patient developed intestinal obstruction with 
important colonic distension and air–liquid levels in 
the abdomen radiograph.
Abdominopelvic CT revealed colonic distension 
induced by anorectal polypoid lesion measuring 
11×7×8 cm, two perirectal tissue lesions adja-
cent to rectosigmoid transition, and multiple lytic 
lesions in the lumbar column and pelvis (figure 3).
DIFFERENTIAL DIAGNOSIS
 ► Solitary anal plasmacytoma
 ► Squamous cell carcinoma
 ► Adenocarcinoma
 ► Small cell carcinoma
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Figure 1 Flexible sigmoidoscopy revealing a large 
polypoid lesion with proximal anal and distal rectal 
involvement covering about one-third of the rectal lumen.
Figure 2 Histopathological examination of the 
anorectal lesion showing subepithelial plasmacytic cell 
infiltration (A). Immunohistochemical staining positive 
for CD138 (B) and CD38 (C), with restraint expression of 
lambda chains (D).
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 ► Lymphoma of the anal canal
 ► Giant condyloma
TREATMENT
After discussion with haematology and surgery, the patient 
started high-dose dexamethasone (40 mg per day for 2 days) 
with clinical resolution of the obstruction. Treatment with 
VCD (bortezomib, cyclophosphamide and dexamethasone) was 
started.
OUTCOME AND FOLLOW-UP
After two VCD cycles, the disease progressed to secondary plasma 
cell leukaemia, showing leucocytosis of 100 000×109 with 69% 
of circulating plasma cells, thrombocytopaenia (platelet count 
46×109 cells/L) and anaemia (haemoglobin 6.3 g/dL). There was 
recurrence of anal obstruction requiring derivative colostomy. 
Despite poor prognosis, he started treatment with VDT-PACE 
(bortezomib, dexamethasone, thalidomide, cisplatin, doxoru-
bicin, cyclophosphamide and etoposide), but died 2 months 
after diagnosis from alveolar haemorrhage.
DISCUSSION
Gastrointestinal involvement at the time of initial diagnosis of 
multiple myeloma is extremely rare and, when present, is usually 
associated with rapid progression of the disease.1 The median 
overall survival in a large retrospective study of patients with 
multiple myeloma involving the gastrointestinal system was 7 
months. Gastrointestinal plasmacytomas may affect any part 
of the gastrointestinal tract, but the small bowel is the most 
common site of infiltration, followed by the stomach, colon and 
oesophagus.1 They account for <5% of all extramedullary plas-
macytoma.1
Clinical manifestations depend on the site and extension of 
involvement and may range from nausea, vomiting, weight loss 
obstruction and bleeding.2
Few cases of anal solitary plasmacytoma have been reported 
in the literature, and the patients were successfully treated with 
radiotherapy.3 4 To our knowledge this is the first case of anal 
plasmacytoma associated with multiple myeloma reported to 
date.
Treatment with high-dose dexamethasone was transiently 
effective in our patient in reducing tumour volume and allowed 
colonic decompression. However, due to disease progression 
under treatment, he ultimately required derivative colostomy. 
The disease eventually progressed with a fatal outcome, as 
expected in cases refractory to bortezomib and immunomodu-
latory drugs.
Learning points
 ► Unlike solitary lesions, which are preferably treated with 
surgical resection and/or radiotherapy, gastrointestinal 
plasmacytomas associated with multiple myeloma 
require a more aggressive approach, reserving surgery 
and radiotherapy for cases of uncontrolled bleeding and 
obstruction.5
 ► Intensive chemotherapy bortezomib-based regimens 
are recommended, followed by autologous stem cell 
transplantation.6 The regimen VDT-PACE (bortezomib, 
dexamethasone, thalidomide, cisplatin, doxorubicin, 
cyclophosphamide and etoposide) is of particular value 
in these patients who present with aggressive disease 
on diagnosis, as in extramedullary gastrointestinal 
plasmacytomas or plasma cell leukaemia.
 ► Allogeneic transplantation can be considered in younger 
patients.7 However, new therapeutic approaches are 
necessary in this limited prognosis scenario, and the patients 
should always be considered for clinical trials.
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Figure 3 Abdominopelvic CT showing anorectal polypoid lesion 
measuring 11×7×8 cm (A), perirectal tissue lesion adjacent to 
rectosigmoid transition (B) and lytic lesion in the pelvis (C).
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